Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Exploring social media for patient perspectives of sickle cell disease.

Liao BT, Busse J, Ender KL, Schechter WS.

Pediatr Hematol Oncol. 2016 Mar;33(2):134-5. doi: 10.3109/08880018.2016.1149261. Epub 2016 Mar 2. No abstract available.

PMID:
26934042
2.

Use of a clinical pathway to improve the acute management of vaso-occlusive crisis pain in pediatric sickle cell disease.

Ender KL, Krajewski JA, Babineau J, Tresgallo M, Schechter W, Saroyan JM, Kharbanda A.

Pediatr Blood Cancer. 2014 Apr;61(4):693-6. doi: 10.1002/pbc.24864. Epub 2013 Nov 19.

PMID:
24249617
3.

Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea.

Green NS, Ender KL, Pashankar F, Driscoll C, Giardina PJ, Mullen CA, Clark LN, Manwani D, Crotty J, Kisselev S, Neville KA, Hoppe C, Barral S.

PLoS One. 2013;8(2):e55709. doi: 10.1371/journal.pone.0055709. Epub 2013 Feb 7.

4.

Fetal hemoglobin levels in African American and Hispanic children with sickle cell disease at baseline and in response to hydroxyurea.

Ender KL, Lee MT, Sheth S, Licursi M, Crotty J, Barral S, Green NS.

J Pediatr Hematol Oncol. 2011 Oct;33(7):496-9. doi: 10.1097/MPH.0b013e31822dcc21.

5.

Safety of short-term valacyclovir as an anti-sickling agent in sickle-cell anemia.

Ender KL, DeBellis RH, Erlanger BF, Billote GB, Brittenham GM.

Pediatr Blood Cancer. 2011 May;56(5):843-5. doi: 10.1002/pbc.22809. Epub 2011 Jan 13.

Supplemental Content

Loading ...
Support Center